An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes

Journal of Medical Economics

Volumn 18, Issue 3, 2015, Pages 230-240

  Home, Philip ^a   Baik, Sei Hyun ^b   Gálvez, Guillermo González ^c   Malek, Rachid ^d   Nikolajsen, Annie ^e  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Korea University College of Medicine   (South Korea)

^c Instituto Jalisciense de Investigacion en Diabetes y Obesidad   (Mexico)

^d Setif 1 University   (Algeria)

^e NOVO NORDISK A S   (Denmark)

Author keywords

A1chieve; Cost effectiveness; Insulin detemir; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; ALGERIA; AMPUTATION; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DRUG COST; END STAGE RENAL DISEASE; EYE DISEASE; FEMALE; HEALTH CARE COST; HEALTH STATUS; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INCIDENCE; INDIA; INDONESIA; INSULIN TREATMENT; LACTIC ACIDOSIS; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEXICO; MIDDLE AGED; MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SOUTH KOREA; VISUAL IMPAIRMENT; AGED; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DIABETES MELLITUS, TYPE 2; ECONOMICS; GROSS NATIONAL PRODUCT; STATISTICAL MODEL;

ADULT; AGED; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 2; FEMALE; GROSS DOMESTIC PRODUCT; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN DETEMIR; LIFE EXPECTANCY; MALE; MEXICO; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS;

EID: 84929335178     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.985788     Document Type: Article

References (42)

1. International Diabetes Federation. Brussels, Belgium: IDF. Last updated 2012. IDF Diabetes Atlas Update. 2012. http://www.idf.org/diabetesatlas
2. Whiting DR, Guariguata L, Weil C, et al. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21
3. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007;57:455-60
4. Del Prato S, Felton AM, Munro N, et al. Improving glucose management: ten stops to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005;59:1345-55
5. Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1cheive study. Diabetes Res Clin Pract 2011;94:352-63
6. Valensi P, Benroubi M, Borzi V, et al; IMPROVE Study Group Expert Panel. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 2009;63:522-31
7. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009;63:6-10
8. Goodall G, Sarpong EM, Hayes C, et al. The consequences of delaying insulin intitiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord 2009;9:19
9. Ringborg A, Cropet C, Jönsson B, et al. Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int J Clin Pract 2009;63:997-1007
10. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013;19:S1-48
11. International Diabetes Federation. Global guideline for type 2 diabetes. 2012. Brussels, Belgium: IDF. http://www.idf.org/global-guideline-type-2-diabetes-2012. Accessed January 3, 2013
12. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1364-79
13. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006;29:1269-74
14. Papa G, Degano C, Iurato P, et al. Efficacia e sicurezza di detemir vs glargine in aggiunta a metformina e repaglinide in pazienti con diabete mellito di tipo 2 non adeguatamente controllati dagli ipoglicemizzanti orali. G It Diabetol Metab 2011;31:192-8
15. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral anti-diabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
16. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial. Randomised addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
17. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia 2008;51:408-16
18. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51
19. Dornhorst A, Lüddeke HJ, Sreenan S, et al; PREDICTIVE Study Group. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008;62:659-65
20. Hajos TR, Pouwer F, de Grooth R, et al. Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care. Diabet Med 2011;28:1096-102
21. Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418-27
22. Schreiber SA, Ferlinz K, Haat T. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther 2008;10:121-7
23. Selam JL, Koenen C, Weng W, et al. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008;24:11-20
24. Baik S, Chacra AR, Yuxiu L, et al. Conducting cost-effectiveness analyses of type 2 diabetes in low-and middle-income countries: can locally generated observational study data overcome methodological limitations? Diabetes Res Clin Pract 2010;88(1 Suppl):S17-22
25. Shah S, Zilov A, Malek R, et al. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study. Diabetes Res Clin Pract 2011;94:364-70
26. Hnoosh A, Vega-Hernández G, Jugrin A, et al. Direct medical management costs of diabetes-related complications in Algeria. Value Health 2012;15:A179
27. Todorova L, Hnoosh A, Bloomfield E, et al. Estimating the direct medical costs associated with diabetes mellitus-related complications in Indonesia. Value Health 2012;15:A662
28. Todorova L, Hnoosh A, Korde G, et al. Direct medical costs of diabetes mellitus-related complications in India. Value Health 2012;15:A662
29. Vega-Hernández G, Jugrin A, Radford M, et al. Direct medical costs of treating diabetes related complications in Mexico. Value Health 2012; 15: A179
30. World Health Organization. WHO Mortality Database. 2012. Geneva, Switzerland: WHO. http://www.who.int/healthinfo/mortality-data/en/. Accessed January 3, 2014
31. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20:S5-26
32. The World Bank. World Bank Open Data. 2012. Washington D.C, USA: The World Bank Group. http://data.worldbank.org/. Accessed January 4, 2014
33. World Health Organization. Choosing interventions that are cost effective. 2013. Geneva, Switzerland: WHO. http://www.who.int/choice/en/. Accessed January 4, 2014
34. Home P, Gálvez GG, Malek R, et al. Short and long-term cost-effectiveness of starting insulin detemir in insulin-naive people with type-2 diabetes. Value Health 2013;16:A164
35. Home P, Balkau BJ, Danchin N, et al. Beginning insulin in people with type 2 diabetes mellitus in real-life practice-1-year results of the 4-year CREDIT study. Diabetologia 2010;53(1 Suppl):S380
36. Valentine WJ, Erny-Albrecht KM, Ray JA, et al. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Adv Ther 2007;24:273-90
37. Valentine WJ, Goodall G, Aagren M, et al. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Adv Ther 2008;25:567-84
38. Arredondo A, de Icaza E. Costos de la diabetes en América Latina: evidencias del caso mexico. Value Health 2011;14:S85-8
39. Boutayeb A, Lamlili M, Boutayeb W, et al. The rise of diabetes in the Arab region. Open J Epidemiol 2012;2:55-60
40. Kim S. Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States. Diabetes Care 2007;30:1281-2
41. Tesfaye S, Gill G. Chronic diabetic complications in Africa. Afr J Diabetes Med 2011;19:4-8
42. Tharkar S, Devarajan A, Kumpatla S, et al. The socioeconomics of diabetes from a developing country: a population based cost of illness study. Diabetes Res Clin Pract 2010;89:334-40